Correlates of survival after autoantibody reduction therapy for acute IPF exacerbations

BACKGROUND: No medical treatment has proven efficacy for acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF), and this syndrome has a very high mortality. Based on data indicating humoral autoimmune processes are involved in IPF pathogenesis, we treated AE-IPF patients with an autoantibody...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulkarni, Tejaswini, Valentine, Vincent G., Fei, Fei, Tran-Nguyen, Thi K., Quesada-Arias, Luisa D., Mkorombindo, Takudzwa, Pham, Huy P., Simmons, Sierra C., Dsouza, Kevin G., Luckhardt, Tracy, Duncan, Steven R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610261/
https://www.ncbi.nlm.nih.gov/pubmed/34813613
http://dx.doi.org/10.1371/journal.pone.0260345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610261/
https://www.ncbi.nlm.nih.gov/pubmed/34813613
http://dx.doi.org/10.1371/journal.pone.0260345

Ejemplares similares